Previous 10 | Next 10 |
home / stock / tltff / tltff news
--News Direct-- Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive Bladder Cancer clinical study. DuMoulin-White shared the significant findings from the study, revealing that ...
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("...
TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("...
TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compou...
(NewsDirect) Theralase Technologies Inc. CEO Roger DuMoulin-White, joined Proactive's Stephen Gunnion to discuss the company's third-quarter 2023 operational highlights. The company successfully raised $1.17 million, crucial for advancing its Phase II clinical study targeting non-musc...
2023-11-30 09:42:30 ET More on Theralase Technologies: Historical earnings data for Theralase Technologies Inc. Financial information for Theralase Technologies Inc. For further details see: Theralase Technologies reports results for the nine month period ended S...
TORONTO, ON / ACCESSWIRE / November 29 th , 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compoun...
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("...
TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" ...
TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" P...
News, Short Squeeze, Breakout and More Instantly...
Theralase Technologies Inc. Company Name:
TLTFF Stock Symbol:
OTCMKTS Market:
Theralase Technologies Inc. Website:
TORONTO, ON / ACCESSWIRE / July 8, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ...
TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formu...
TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formu...